Search

Displaying results 5441 - 5450 of 10000 in total
  1. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.

  2. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Ecallantide works by blocking kallikrein to participate in the kallikrein-kinin system, which is a complex proteolytic cascade that initiates inflammatory and coagulation pathways [FDA Label]. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.

  3. Drug

    TAS-108

    go.drugbank.com/drugs/DB05966
    Investigational

  4. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

  5. Drug

    Gossypol acetic acid

    go.drugbank.com/drugs/DB31699
    Investigational

    Categories: Hormonal Contraceptives for Systemic Use
  6. Drug

    Elsamitrucin

    go.drugbank.com/drugs/DB05129
    Investigational

    The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)

  7. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    Amylmetacresol is often combined with dichlorobenzyl alcohol and menthol in the commonly used sore throat lozenges, known as Strepsils [L2575]. … Pharyngitis is normally caused by viruses and proves benign and self-limiting.

  8. Drug

    DLO6002

    go.drugbank.com/drugs/DB05179
    Experimental

    DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.

  9. Drug

    Gantacurium

    go.drugbank.com/drugs/DB05710
    Investigational

    Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.

  10. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist.